Combination Therapy of Colon Carcinoma 26 in Mice with Recombinant Human Interleukin-2 and Interferon-α A/D: Occurrence of Large Granular Cells in the Tumor
- 1 September 1989
- journal article
- research article
- Published by Wiley in Japanese Journal of Cancer Research
- Vol. 80 (9) , 895-903
- https://doi.org/10.1111/j.1349-7006.1989.tb01732.x
Abstract
The antitumor effects of recombinant human interleukin-2 (rIL-2), in combination with recombinant human interferon-.alpha. A/D hybrid (rIFN-.alpha. A/D) on colon carcinoma 26 (colon 26) in mice were examined histologically. Colon 26 was transplanted subcutaneously into female BALB/c mice on day 0. The mice bearing the tumor received intramuscular injection of rIL-2, rIFN-.alpha. A/D or the combination of rIL-2 and rIFN-.alpha. A/D for 2-10 consecutive days starting on day 7. Mice were killed on days 9, 13, 17 and 21. After day 13, growth of the tumor was significantly suppressed in the mice treated with rIL-2 or rIFN-.alpha. A/D alone and was stopped in the mice treated with rIL-2 in combination with rIFN-.alpha. A/D. Histologically, tumor necrosis developed in all treated groups, though the degree was the most severe in the group receiving combination treatment. Many large cells (about 15-30 .mu.m in diameter) infiltrated into the tumor, and they had Thy-1 surface antigen and many periodic acid-Schiff-positive round granules in the cytoplasm. The incidence of these large granular cells was correlated well with the reduction in tumor weight. The ultrastructural features of the large granular cells were very similar to those of murine large granular lymphocyte-like cells maintained in vitro in an IL-2-containing medium. The present large granular cells appear to be a kind of activated lymphoid cells.Keywords
This publication has 49 references indexed in Scilit:
- Therapeutic efficacy of human recombinant interleukin-2 (TGP-3) alone or in combination with cyclophosphamide and immunocompetent cells in allogeneic, semi-syngeneic, and syngeneic murine tumorsCancer Immunology, Immunotherapy, 1989
- In vivo anti‐tumor activity of combinations of interferon alpha and interleukin‐2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cellsInternational Journal of Cancer, 1987
- Expression and rearrangement of the alpha, beta, and gamma chain genes of the T cell receptor in cloned murine large granular lymphocyte lines. No correlation with the cytotoxic spectrum.The Journal of Experimental Medicine, 1986
- Cancer Immunotherapy Using Interleukin-2 and Interleukin-2-Activated LymphocytesAnnual Review of Immunology, 1986
- Purification and characterization of recombinant human interleukin-2 produced in Escherichia coliBiochemical and Biophysical Research Communications, 1985
- Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.The Journal of Experimental Medicine, 1985
- Comparison of the biological properties of purified natural and recombinant human interleukin-2Biochemical and Biophysical Research Communications, 1985
- Inhibition of experimentally‐induced murine metastases by recombinant alpha interferon: Correlation between the modulatory effect of interferon treatment on natural killer cell activity and inhibition of metastasesInternational Journal of Cancer, 1984
- Cloned mouse cells with natural killer function and cloned suppressor T cells express ultrastructural and biochemical features not shared by cloned inducer T cells.The Journal of Experimental Medicine, 1983
- Translation of interleukin 2 mRNA from human peripheral blood leukocytes in Xenopus oocytesBiochemical and Biophysical Research Communications, 1982